Idiopathic Membranous Nephropathy Market

DelveInsight's "Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Idiopathic Membranous Nephropathy, historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Idiopathic Membranous Nephropathy market report provides current treatment practices, emerging drugs, Idiopathic Membranous Nephropathy market share of the individual therapies, current and forecasted Idiopathic Membranous Nephropathy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Idiopathic Membranous Nephropathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Idiopathic Membranous Nephropathy market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

Idiopathic Membranous Nephropathy Disease Understanding and Treatment Algorithm

Idiopathic membranous nephropathy is one of the most common glomerular disease associated with nephrotic syndrome. Membranous nephropathy is the result of the damage in the blood vessels of the nephron (filters) of the kidney. This leads to proteinuria, a condition which involves draining of proteins in the urine due to thickening of the walls of the blood vessels which in return increases the chances of kidney failure. There is no specific treatment available for the condition but if treated correctly, it can be controlled.

 

The Idiopathic membranous nephropathy symptoms include:

  • Swelling in the legs
  • Weight gain
  • Poor appetite
  • High cholesterol
  • Fatigue
  • Acute and chronic kidney failure

There are two categories of membranous nephropathy, which are, primary and secondary membranous nephropathy. Primary membranous nephropathy occurs when the body‘s antibodies attack healthy cells in the body, and secondary membranous nephropathy occurs as a result of certain  conditions like hepatitis B, hepatitis C, syphilis, internalization of medications like NSAIDs, gold salts, tumors etc.

 

Idiopathic Membranous Nephropathy Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Idiopathic Membranous Nephropathy.

 

Idiopathic Membranous Nephropathy Treatment

It covers the details of conventional and current medical therapies available in the Idiopathic Membranous Nephropathy market for the treatment of the condition. It also provides Idiopathic Membranous Nephropathy treatment algorithms and guidelines in the United States, Europe, and Japan.

Idiopathic Membranous Nephropathy Epidemiology 

The Idiopathic Membranous Nephropathy epidemiology section provides insights about the historical and current Idiopathic Membranous Nephropathy patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Idiopathic Membranous Nephropathy market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Idiopathic Membranous Nephropathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

  • North America is expected to maintain the dominating position in the global idiopathic membranous nephropathy market due to the high prevalence of idiopathic membranous nephropathy in the area

 

  • According to the clinical journal of the American Society of Nephrology, 2017, about 12 million persons in North America between the ages of 50 and 60 suffer from idiopathic membranous nephropathy each year. 

 

  • The National Institute of Allergy and Infectious Diseases (NIAID), the Immune Tolerance Network, and GlaxoSmithkline are now collaborating to better understand the effect of belimumab and rituximab combination therapy on patients with idiopathic membranous nephropathy. The phase II investigation began in December 2019 and is anticipated to be completed in February 2025.

 

  • In a clinical trial, 60 percent of patients suffering from membranous nephropathy showed a positive response to rituximab treatment in a study comparing the efficacy of rituximab and cyclosporine while remaining 40 percent patients did not show any response to the treatment, as per the New England Journal of Medicine, 2019

 

Country Wise- Idiopathic Membranous Nephropathy Epidemiology

The epidemiology segment also provides the Idiopathic Membranous Nephropathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Idiopathic Membranous Nephropathy Drug Chapters

The drug chapter segment of the Idiopathic Membranous Nephropathy report encloses the detailed analysis of Idiopathic Membranous Nephropathy marketed drugs and late-stage (Phase-III and Phase-II) Idiopathic Membranous Nephropathy pipeline drugs. It also helps to understand the Idiopathic Membranous Nephropathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Idiopathic Membranous Nephropathy Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Idiopathic Membranous Nephropathy treatment.

 

Idiopathic Membranous Nephropathy Companies

  • Trevena
  • Heron Therapeutics
  • Cara Therapeutics
  • Neumentum Pharmaceutical
  • Pfizer
  • And many others

 

Idiopathic Membranous Nephropathy Pipeline Treatment

  • Olinvo (Oliceridine injection or TRV130)
  • HTX011
  • CR845/Difelikefalin
  • NTM001
  • PF05089771
  • And many others

 

Idiopathic Membranous Nephropathy Market Outlook

The Idiopathic Membranous Nephropathy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Idiopathic Membranous Nephropathy market trends by analyzing the impact of current Idiopathic Membranous Nephropathy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Idiopathic Membranous Nephropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Idiopathic Membranous Nephropathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Idiopathic Membranous Nephropathy market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Idiopathic Membranous Nephropathy market in 7MM.

 

The United States: Idiopathic Membranous Nephropathy Market Outlook

This section provides the total Idiopathic Membranous Nephropathy market size and market size by therapies in the United States.

 

EU-5 Countries: Idiopathic Membranous Nephropathy Market Outlook

The total Idiopathic Membranous Nephropathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan: Idiopathic Membranous Nephropathy Market Outlook

The total Idiopathic Membranous Nephropathy market size and market size by therapies in Japan is also mentioned.

Idiopathic Membranous Nephropathy Drugs Uptake

This section focuses on the rate of uptake of the potential Idiopathic Membranous Nephropathy drugs recently launched in the Idiopathic Membranous Nephropathy market or expected to get launched in the market during the study period 2019-2032. The analysis covers Idiopathic Membranous Nephropathy market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Idiopathic Membranous Nephropathy Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Idiopathic Membranous Nephropathy market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Idiopathic Membranous Nephropathy Pipeline Development Activities

The Idiopathic Membranous Nephropathy report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Idiopathic Membranous Nephropathy key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The Idiopathic Membranous Nephropathy report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Idiopathic Membranous Nephropathy emerging therapies.

Reimbursement Scenario in Idiopathic Membranous Nephropathy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Idiopathic Membranous Nephropathy market trends, we take KOLs and SMEs ' opinion working in the Idiopathic Membranous Nephropathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Idiopathic Membranous Nephropathy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Idiopathic Membranous Nephropathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Idiopathic Membranous Nephropathy Report

  • The report covers the descriptive overview of Idiopathic Membranous Nephropathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Idiopathic Membranous Nephropathy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Idiopathic Membranous Nephropathy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Idiopathic Membranous Nephropathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Idiopathic Membranous Nephropathy market

Idiopathic Membranous Nephropathy Report Highlights

  • In the coming years, the Idiopathic Membranous Nephropathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Membranous Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Idiopathic Membranous Nephropathy. The launch of emerging therapies will significantly impact the Idiopathic Membranous Nephropathy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Idiopathic Membranous Nephropathy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Idiopathic Membranous Nephropathy Report Insights

  • Idiopathic Membranous Nephropathy Patient Population
  • Therapeutic Approaches
  • Idiopathic Membranous Nephropathy Pipeline Analysis
  • Idiopathic Membranous Nephropathy Market Size
  • Idiopathic Membranous Nephropathy Market Trends
  • Idiopathic Membranous Nephropathy Market Opportunities
  • Impact of upcoming Idiopathic Membranous Nephropathy Therapies

Idiopathic Membranous Nephropathy Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Idiopathic Membranous Nephropathy Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Idiopathic Membranous Nephropathy Market
  • Idiopathic Membranous Nephropathy Drugs Uptake

Idiopathic Membranous Nephropathy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Idiopathic Membranous Nephropathy Pipeline Product Profiles
  • Idiopathic Membranous Nephropathy Market Attractiveness
  • Idiopathic Membranous Nephropathy Market Drivers
  • Idiopathic Membranous Nephropathy Market Barriers

Key Questions

Idiopathic Membranous Nephropathy Market Insights:

  • What was the Idiopathic Membranous Nephropathy drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Idiopathic Membranous Nephropathy total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Idiopathic Membranous Nephropathy market size during the forecast period (2019-2032)?
  • At what CAGR, the Idiopathic Membranous Nephropathy market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Idiopathic Membranous Nephropathy market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Idiopathic Membranous Nephropathy market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the Idiopathic Membranous Nephropathy?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Idiopathic Membranous Nephropathy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Idiopathic Membranous Nephropathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Idiopathic Membranous Nephropathy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Idiopathic Membranous Nephropathy during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Idiopathic Membranous Nephropathy treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Idiopathic Membranous Nephropathy in the USA, Europe, and Japan?
  • What are the Idiopathic Membranous Nephropathy marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Idiopathic Membranous Nephropathy?
  • How many therapies are in-development by each company for Idiopathic Membranous Nephropathy treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Idiopathic Membranous Nephropathy treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Idiopathic Membranous Nephropathy therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Idiopathic Membranous Nephropathy and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Idiopathic Membranous Nephropathy?
  • What are the global historical and forecasted market of Idiopathic Membranous Nephropathy?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Idiopathic Membranous Nephropathy market
  • To understand the future market competition in the Idiopathic Membranous Nephropathy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Membranous Nephropathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Membranous Nephropathy market
  • To understand the future market competition in the Idiopathic Membranous Nephropathy market

1. Key Insights

2. Executive Summary of Idiopathic Membranous Nephropathy

3. Competitive Intelligence Analysis for Idiopathic Membranous Nephropathy

4. Idiopathic Membranous Nephropathy: Market Overview at a Glance

4.1. Idiopathic Membranous Nephropathy Total Market Share (%) Distribution in 2019

4.2. Idiopathic Membranous Nephropathy Total Market Share (%) Distribution in 2032

5. Idiopathic Membranous Nephropathy: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Idiopathic Membranous Nephropathy Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Idiopathic Membranous Nephropathy Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Idiopathic Membranous Nephropathy Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Idiopathic Membranous Nephropathy Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Idiopathic Membranous Nephropathy Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Idiopathic Membranous Nephropathy Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Idiopathic Membranous Nephropathy Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Idiopathic Membranous Nephropathy Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Idiopathic Membranous Nephropathy Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Idiopathic Membranous Nephropathy Treatment and Management

8.2. Idiopathic Membranous Nephropathy Treatment Algorithm

9. Idiopathic Membranous Nephropathy Unmet Needs

10. Key Endpoints of Idiopathic Membranous Nephropathy Treatment

11. Idiopathic Membranous Nephropathy Marketed Products

11.1. List of Idiopathic Membranous Nephropathy Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Idiopathic Membranous Nephropathy Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Idiopathic Membranous Nephropathy: Seven Major Market Analysis

13.1. Key Findings

13.2. Idiopathic Membranous Nephropathy Market Size in 7MM

13.3. Idiopathic Membranous Nephropathy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Idiopathic Membranous Nephropathy Market Outlook

15.1. United States: Idiopathic Membranous Nephropathy Market Size

15.1.1. Idiopathic Membranous Nephropathy Total Market Size in the United States

15.1.2. Idiopathic Membranous Nephropathy Market Size by Therapies in the United States

15.2. EU-5 countries: Idiopathic Membranous Nephropathy Market Size and Outlook

15.3. Germany Idiopathic Membranous Nephropathy Market Size

15.3.1. Idiopathic Membranous Nephropathy Total Market Size in Germany

15.3.2. Idiopathic Membranous Nephropathy Market Size by Therapies in Germany

15.4. France Idiopathic Membranous Nephropathy Market Size

15.4.1. Idiopathic Membranous Nephropathy Total Market Size in France

15.4.2. Idiopathic Membranous Nephropathy Market Size by Therapies in France

15.5. Italy Idiopathic Membranous Nephropathy Market Size

15.5.1. Idiopathic Membranous Nephropathy Total Market Size in Italy

15.5.2. Idiopathic Membranous Nephropathy Market Size by Therapies in Italy

15.6. Spain Idiopathic Membranous Nephropathy Market Size

15.6.1. Idiopathic Membranous Nephropathy Total Market Size in Spain

15.6.2. Idiopathic Membranous Nephropathy Market Size by Therapies in Spain

15.7. United Kingdom Idiopathic Membranous Nephropathy Market Size

15.7.1. Idiopathic Membranous Nephropathy Total Market Size in the United Kingdom

15.7.2. Idiopathic Membranous Nephropathy Market Size by Therapies in the United Kingdom

15.8. Japan Idiopathic Membranous Nephropathy Market Outlook

15.8.1. Japan Idiopathic Membranous Nephropathy Market Size

15.8.2. Idiopathic Membranous Nephropathy Total Market Size in Japan

15.8.3. Idiopathic Membranous Nephropathy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Idiopathic Membranous Nephropathy

17. KOL Views

18. Idiopathic Membranous Nephropathy Market Drivers

19. Idiopathic Membranous Nephropathy Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM Idiopathic Membranous Nephropathy Epidemiology (2019-2032)

Table 2: 7MM Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases (2019-2032)

Table 3: Idiopathic Membranous Nephropathy Epidemiology in the United States (2019-2032)

Table 4: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Idiopathic Membranous Nephropathy Epidemiology in Germany (2019-2032)

Table 6: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Idiopathic Membranous Nephropathy Epidemiology in France (2019-2032)

Table 8: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Idiopathic Membranous Nephropathy Epidemiology in Italy (2019-2032)

Table 10: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Idiopathic Membranous Nephropathy Epidemiology in Spain (2019-2032)

Table 12: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Idiopathic Membranous Nephropathy Epidemiology in the UK (2019-2032)

Table 14: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Idiopathic Membranous Nephropathy Epidemiology in Japan (2019-2032)

Table 16: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Idiopathic Membranous Nephropathy Epidemiology (2019-2032)

Figure 2: 7MM Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases (2019-2032)

Figure 3: Idiopathic Membranous Nephropathy Epidemiology in the United States (2019-2032)

Figure 4: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Idiopathic Membranous Nephropathy Epidemiology in Germany (2019-2032)

Figure 6: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Idiopathic Membranous Nephropathy Epidemiology in France (2019-2032)

Figure 8: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Idiopathic Membranous Nephropathy Epidemiology in Italy (2019-2032)

Figure 10: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Idiopathic Membranous Nephropathy Epidemiology in Spain (2019-2032)

Figure 12: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Idiopathic Membranous Nephropathy Epidemiology in the UK (2019-2032)

Figure 14: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Idiopathic Membranous Nephropathy Epidemiology in Japan (2019-2032)

Figure 16: Idiopathic Membranous Nephropathy Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

  • Trevena
  • Heron Therapeutics
  • Cara Therapeutics
  • Neumentum Pharmaceutical
  • Pfizer

 

Forward to Friend

Need A Quote